New User Account Set Up

If you do not have an account with the Digest, please click on "Submit to the Digest." By logging in with your UCLA Login ID (formerly known as BOL Login), a new account will automatically be generated. If you experience any difficulties, please send an email to our help desk:


If you have any questions or concerns, please email our help desk/support team: We are more than happy to address any questions or concerns regarding the Weekly Message Digest system you may have.

How do I subscribe?

If you have a mednet email account (, you should already be subscribed.

If you do not have a mednet email account or you are not receiving the Digest, please send an email to and we will add you to our list.

A Study for Persons with Excessive Weight Gain on Integrase Inhibitors and Tenofovir

The Do IT Study is looking for people living with HIV who have experienced weight gain from taking a treatment regimen that contains both an integrase inhibitor (such as bictegravir, dolutegravir, or raltegravir) and “new” tenofovir (TAF, tenofovir alafenamide). One group will either stay on their present regimen, two groups will switch out one or two medications to a new regimen. This study will assess whether the new combinations reduce weight gain or possibly reverses the weight gain over 48 weeks compared to people who remain on their current ART.


Basic eligibility criteria:

  • Age 18+
  • Living with HIV
  • Currently on an ART regimen containing an integrase inhibitor and tenofovir alafenamide (TAF) with no interruption over 48 weeks
  • Have experienced > 10% weight gain in 1-3 years after starting these medications
  • Have a body mass index (BMI) > 27.5kg/m^2


Exclusion Criteria:

  • Breastfeeding or pregnant
  • Recent serious illness or condition requiring hospitalization
  • Plans to undergo weight loss surgery


Principal Investigator: Raphael J. Landovitz, MD, MSc

For more information contact the UCLA study team at (310) 843-2015 or

Posting Information
This posting expired on September 04, 2022.
Posting Attachment: Download Attachment

Share this posting on social media!